, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms tumors[J]. Lab Invest, 2003，83:429-443
[21]Suraweera N, Robinson J, Volikos E, et al. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines[J]. Int J Cancer, 2006，119:1837-1842
[22]Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1(DKK-1) gene in human colorectal cancer[J]. Oncogene, 2006，25:4116-4121
[23] Mueller W, Lass U, Wellmann S, et al. Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas[J]. Acta Neuropathol (Berl), 2005，109:314-320
[24]Rodríguez-Sastre MA, González-Maya L, Delgado R, et al. Abnormal distribution of E-cadherin and β-catenin in different histologic types of cancer of the uterine cervix[J]. Gynecol Oncol, 2005,97(2):330-336
[25]Lee J, Yoon YS, Chung JH. Epigenetic silencing of the WNTantagonist DICKKOPF-1in cervical cancer cell lines[J]. Gynecol Oncol, 2008,109(2):270-274
[26]Uren A, Fallen S, Yuan H, et al. Activation of the canonical wnt pathway during genital kerationocyte transformation: A model for cervical cancer progression[J]. Cancer Res, 2005,65(14):6199-6206
[27]Pérez-Plasencia C,Vázquez-Ortiz G,López-Romero R, et al. Genome wide expression analysis in HPV16cervical cancer:identificati-on of metabolic pathways[J]. Infect Agent Cancer, 2007, 2:6-16
[28]Forget MA, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types[J]. Br J Cancer, 2007,96(4):646-65
上一页 [1] [2] [3] [4] [5]
您现在的位置： 绿色健康网 >> 医学论文 >> 妇产科论文 >> 正文